Sign in

    Claire Adison • Independent Investment Research

    Claire Adison is a Senior Analyst at Independent Investment Research, specializing in equity analysis within the Australian market. She provides detailed coverage on companies such as Australian Pharmaceutical Industries, Brickworks Ltd, and Pacific Smiles Group, consistently generating comprehensive investment recommendations for institutional clients. Adison began her career as a financial associate at a boutique advisory firm before transitioning to her current role at Independent Investment Research in 2018, where she continues to expand her remit in the healthcare and industrial sectors. Holding RG146 certification and registered with ASIC, she is recognized for the accuracy and depth of her research, contributing to strong performance outcomes for her clients.

    Claire Adison's questions to Acurx Pharmaceuticals Inc (ACXP) leadership

    Claire Adison's questions to Acurx Pharmaceuticals Inc (ACXP) leadership • Q4 2024

    Question

    Claire Adison from Independent Investment Research asked for clarification on the suspension of the At-The-Market (ATM) financing program and questioned the company's strategy to manage the risk of delisting from NASDAQ.

    Answer

    CFO Robert Shawah explained that the ATM program was suspended in connection with the January registered direct offering and can be reactivated if management chooses, though it is not part of the immediate plan. Shawah expressed strong confidence in maintaining the NASDAQ listing, stating there is "no sense internally that we'll let the NASDAQ listing go" and that the company is actively working on measures to address the situation.

    Ask Fintool Equity Research AI